AlphaMark Advisors LLC Invests $149,000 in Roche Holding AG (OTCMKTS:RHHBY)

AlphaMark Advisors LLC bought a new stake in shares of Roche Holding AG (OTCMKTS:RHHBY) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 3,728 shares of the company’s stock, valued at approximately $149,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Diversified Trust Co lifted its position in Roche by 6.4% during the 3rd quarter. Diversified Trust Co now owns 59,742 shares of the company’s stock worth $2,396,000 after acquiring an additional 3,613 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Roche by 57.7% during the third quarter. GAMMA Investing LLC now owns 7,944 shares of the company’s stock worth $317,000 after purchasing an additional 2,906 shares in the last quarter. Bard Financial Services Inc. boosted its stake in shares of Roche by 112.1% in the third quarter. Bard Financial Services Inc. now owns 66,500 shares of the company’s stock valued at $2,657,000 after purchasing an additional 35,150 shares during the period. Norman Fields Gottscho Capital Management LLC grew its holdings in Roche by 5.5% during the 3rd quarter. Norman Fields Gottscho Capital Management LLC now owns 26,000 shares of the company’s stock valued at $1,039,000 after purchasing an additional 1,350 shares in the last quarter. Finally, Altrius Capital Management Inc increased its stake in Roche by 6.0% during the 2nd quarter. Altrius Capital Management Inc now owns 224,804 shares of the company’s stock worth $7,794,000 after buying an additional 12,646 shares during the period.

Roche Price Performance

RHHBY opened at $39.56 on Friday. Roche Holding AG has a 1-year low of $29.20 and a 1-year high of $42.43. The company has a 50-day moving average of $39.97 and a 200-day moving average of $35.95.

Analysts Set New Price Targets

Several brokerages have recently weighed in on RHHBY. Bank of America upgraded Roche from a “neutral” rating to a “buy” rating in a research note on Friday, September 13th. Deutsche Bank Aktiengesellschaft lowered Roche from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.